BIOFACTURA INC

EOI::PRESIDENTIAL COST SAVINGS INITIATIVE (FEBRUARY 26, 2025)::EOI NOTICE OF TERMINATION FOR CONVENIENCE

THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO ACCOMPLISH ALL OF THE FOLLOWING OBJECTIVES: 1. MOD CLIN0003 TO FUND COA REQUEST 10.3, TO COVER THE CARE AND HANDLING THAT SOUTHERN RESEARCH PROVIDED THE NON-HUMAN PRIMATE SUBJECTS OF THE PK STUDY, PRI

THE PURPOSES OF THIS MODIFICATION ARE TO 1. ADD FUNDING TO OPTION 2 (CLIN 0003) IN THE AMOUNT OF $230,896.03. 2. EXERCISE OPTION 4 (CLIN 0005) IN THE AMOUNT OF $16,012,452.00. 3. CHANGE THE COR FROM MALEN LINK TO CAROL DIAZ-DIAZ

ADD FUNDING TO OPTION 2 (CLIN 0003) IN THE AMOUNT OF $928,249.32. THIS INCLUDES $269,855.08 TO ACCOUNT FOR G&A AND FEE AS WELL AS $658,394.25 FOR ADDITIONAL MANUFACTURE OF ANTI-ID ABS FOR METHODS DEVELOPMENT.

MODIFICATION 12 ADDS FUNDING IN THE AMOUNT OF $1,707,218.18 TO CLIN 0003 OPTION PERIOD 2

THE ADVANCEMENT OF THE DEVELOPMENT OF A SMALLPOX BIODEFENSE THERAPEUTIC TO THE CLINICAL STAGE AS AN ANTIBODY-BASED COUNTERMEASURE